AdvisorShares Pure Cannabis ETF

YOLO

Börsenwert 29,7 Mio. $

Gen Z travelers are cutting back on dining, haircuts and everyday expenses to afford trips as homeownership and other traditional milestones feel increasingly out of reach. #foxbusiness #bigmoneyshow 00:00 Gen Z Reorganizes the American Dream 01:04 Why Homeownership Feels Out of Reach 02:11 Renting, Investing and Building Wealth Differently 03:06 Gen Z Is Starting to Invest Younger 04:59 The Debate Over Living at Home to Save Money

August delivered strong gains across shipping, crypto, precious metals, biotech, copper, uranium and cloud software ETFs.

Limited-license states often favor established cannabis operators. Scale and positive cash flow create lasting competitive advantages.

Trulieve Cannabis is a leading company in the marijuana market, and it's now trading on a major U.S. exchange. As the U.S. government has rescheduled medical marijuana products, it has paved the way for Trulieve to uplist onto the New York Stock Exchange.

The cannabis sector continues to attract investors seeking long-term growth opportunities in 2026. Although volatility remains high, many marijuana companies are improving operations and cutting costs. At the same time, investors continue watching potential federal reform closely. Rescheduling discussions and banking reform could become major catalysts for the industry.

Medical marijuana's US reclassification revives cannabis ETFs like WEED, with tax relief and reform hopes fueling sharp gains across the sector.

For marijuana stock investors, the way the industry as a whole progresses determines a great deal for them. For example, no one wants to invest in a struggling industry even if it's been trendy along the way. Now, cannabis has fallen to that path, but it's also what's making this industry one of the hottest sectors in the last 5 years. Legal cannabis has been a long uphill battle in every sense. Legislation and regulatory issues remain the biggest challenges.

Federal cannabis policy moved from theory to action this spring, and three ETFs sit closest to the trade.

Cannabis stocks have seen renewed investor interest as federal policy momentum improves. The most important recent development was the placement of FDA-approved marijuana products and state-regulated medical marijuana products from Schedule I to Schedule III under the Controlled Substances Act.

Companies developing cannabis-based medicines say U.S. moves to loosen restrictions on the drug could unlock private funding and the public markets, ​providing a lifeline to the struggling cannabis industry.